Taranabant, a novel cannabinoid type 1 receptor inverse agonist
{{output}}
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of tar... ...
